-The group agreed on sets of uniform sampling criteria, placental gross descriptors, pathologic terminologies, and diagnostic criteria. The terminology and microscopic descriptions for maternal vascular malperfusion, fetal vascular malperfusion, delayed villous maturation, patterns of ascending intrauterine infection, and villitis of unknown etiology were agreed upon. Topics requiring further discussion were highlighted. Ongoing developments in our understanding of the pathology of the placenta, scientific bases of the maternofetoplacental triad, and evolution of the clinical significance of defined lesions may necessitate further refinements of these consensus guidelines. The proposed structure will assist in international comparability of clinicopathologic and scientific studies and assist in refining the significance of lesions associated with adverse pregnancy and later health outcomes.

The authors report no conflict of interest.A.C.S. has received, in kind, reagents for soluble fms-like tyrosine kinase 1 and placental growth factor biomarker analyses from Roche Diagnostics (Rotkreuz, Switzerland). Roche Diagnostics had no impact on the planning, performance, or other aspects of the biomarker studies.

No abstract

No abstract